Distribution of Carbapenemase Genes among Carbapenem-Non-Susceptible Acinetobacter baumanii Blood Isolates in Indonesia: A Multicenter Study

Dewi Anggraini 1,2,3, Dewi Santosaningsih 4,5, Yulia Rosa Saharman 6,7, Pepy Dwi Endraswari 8,9, Cahyarini Cahyarini 10, Leli Saptawati 11,12, Zinatul Hayati 13,14, Helmia Farida 15,16, Cherry Siregar 17, Munawaroh Pasaribu 18, Heriyannis Homenta 19, Enty Tjoa 20, Novira Jasmin 2, Rosantia Sarassari 2, Wahyu Setyarini 21, Usman Hadi 9,22 and Kuntaman Kuntaman 8,9,*

1 Doctoral Program, Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia; dewi.anggraini-2019@fk.unair.ac.id
2 Department of Microbiology, Faculty of Medicine, Universitas Riau, Pekanbaru 28133, Indonesia; novirajasminmd@gmail.com
3 Arifin Achmad General Hospital, Pekanbaru 28156, Indonesia
4 Department of Clinical Microbiology, Faculty of Medicine, Universitas Brawijaya, Malang 65145, Indonesia; dewi.santosa@ub.ac.id
5 Dr. Saiful Anwar Hospital, Malang 65112, Indonesia
6 Department of Clinical Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta 10320, Indonesia; yulia.rosa18@gmail.com
7 Pelni Hospital, Jakarta 11410, Indonesia
8 Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia; pepy.dr@fk.unair.ac.id (P.D.E.); santisarassari@yahoo.com (R.S.)
9 Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia; usmanhadi@sby.centrin.net.id
10 Department of Clinical Microbiology, Persahabatan General Hospital, Jakarta 13230, Indonesia; rrin_cahya@yahoo.com
11 Department of Microbiology, Faculty of Medicine, Universitas Sebelas Maret, Surakarta 57126, Indonesia; lelisaptawati@staff.uns.ac.id
12 Department of Microbiology, Dr. Moewardi Teaching Hospital, Surakarta 57126, Indonesia
13 Department of Microbiology, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh 23111, Indonesia; hayatikarmil@unsyiah.ac.id
14 Department of Microbiology, Dr. Zainoel Abidin Hospital, Banda Aceh 24415, Indonesia
15 Department of Microbiology, Faculty of Medicine, Diponegoro University, Semarang 50275, Indonesia; helmia.f@fk.undip.ac.id
16 Dr. Kariadi Hospital, Semarang 50244, Indonesia
17 H. Adam Malik Hospital, Medan 20136, Indonesia; drhrvy@yahoo.com
18 Ulin Hospital, Banjarmasin 70233, Indonesia; munawaroqpasaribu@gmail.com
19 Department of Clinical Microbiology, Faculty of Medicine, University of Sam Ratulangi, Manado 95115, Indonesia; herihomenta@unsrat.ac.id
20 Department of Microbiology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 12930, Indonesia; enty@atmajaya.ac.id
21 Institute of Tropical Disease, Universitas Airlangga, Surabaya 60115, Indonesia; wahyu_setyarini82@yahoo.com
22 Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia
* Correspondence: kuntaman@fk.unair.ac.id; Tel.: +62-31-5020251

Abstract: Carbapenem non-susceptible Acinetobacter baumannii (CNSAB) is an important pathogen that causes nosocomial bacteremia among critically ill patients worldwide. The magnitude of antibiotic resistance of A. baumannii in Indonesia is expected to be significant; however, the data available are limited. The aim of this study was to analyze the genetic profiles of CNSAB isolates from patients with bacteremia in Indonesia. CNSAB isolates from blood cultures of bacteremia patients in 12 hospitals in Indonesia were included. The blood cultures were conducted using the BacT/Alert or BACTEC automated system. The CNSAB were identified with either Vitek 2 system or Phoenix platform followed by a confirmation test using a multiplex polymerase chain reaction (PCR) assay, targeting the specific gyrB gene. The carbapenemase genes were detected by multiplex PCR. In total, 110 CNSAB isolates were collected and were mostly resistant to nearly all
antibiotic classes. The majority of CNSAB isolates were susceptible to tigecycline and trimethoprim-sulfamethoxazole (TMP-SMX), 45.5% and 38.2%, respectively. The \textit{bla}_{OXA-51-like} gene was identified in all CNSAB isolates. Out of the total, 83.6% of CNSAB isolates had \textit{bla}_{OXA-23-like} gene, 37.3% \textit{bla}_{OXA-24-like} gene, 4.5% \textit{bla}_{NDM-1} gene, 0.9% \textit{bla}_{IMP-1} gene, and 0.9% \textit{bla}_{VIM} gene. No \textit{bla}_{OXA-48-like} gene was identified. The \textit{bla}_{OXA-23-like} gene was the predominant gene in all except two hospitals. The presence of the \textit{bla}_{OXA-24-like} gene was associated with resistance to tigecycline, amikacin, TMP-SMX and cefoperazone-sulbactam, while \textit{bla}_{OXA-23-like} gene was associated with resistance to TMP-SMX and cefoperazone-sulbactam. In conclusion, the \textit{bla}_{OXA-23-like} gene was the predominant gene among CNSAB isolates throughout Indonesia. A continuous national surveillance system needs to be established to further monitor the genetic profiles of CNSAB in Indonesia.

**Keywords:** infectious disease; Acinetobacter baumannii; CNSAB; carbapenemase gene; resistant factor; Indonesia

1. Introduction

*Acinetobacter baumannii* (*A. baumannii*) is a non-motile, glucose-non-fermenting oxidase-negative Gram-negative bacterium [1]. It is recognized as a main pathogen causing hospital-acquired infections worldwide and is responsible for 2–10% of all Gram-negative hospital-acquired infections [2,3]. The infections are common in immunocompromised individuals, in particular those who have been hospitalized for a long time due to major surgical procedures or other underlying diseases [4,5]. The ability of this bacterium to thrive in a variety of environments with low nutrition is a key component of its pathogenesis [1]. *A. baumannii* can cause bacteremia, ventilator-associated pneumonia, infections of urinary tract, skin and soft tissues, burn and surgical wound infections, osteomyelitis and meningitis [1,6]. The bacteria could easily enter the human body through open wounds, intravascular catheters and mechanical ventilators [3,5]. The mortality rate of bacteremia due to *A. baumannii* ranges from 30–40% [7].

*A. baumannii* is intrinsically resistant and acquired resistant to various antibiotics [8]. It has a high level of intrinsic resistance to antimicrobial groups such as macrolides, lincosamides, glycopeptides and streptogramins [1]. In addition, it is also able to develop resistance to almost all classes of antibiotics. Some of the resistance mechanisms of *A. baumannii* include producing \(\beta\)-lactamases, overexpression of intrinsic antibiotic modifying enzymes, efflux pumps, permeability defects, and modifications of target sites of the antibiotics [1,9]. All these mechanisms lead to significant challenges in treating *A. baumannii* infections due to decreased number of available antibiotics in the clinical setting [1,9].

Carbapenems (imipenem, meropenem and doripenem) are considered as effective antibiotics for *A. baumannii* infection; however, resistance to this antibiotic class makes *A. baumannii*-associated infections difficult to be treated [10]. The prevalence of carbapenem non-susceptible *A. baumannii* (CNSAB) is increasing worldwide, including in Indonesia [11–14]. The main resistance mechanism of CNSAB is to produce \(\beta\)-lactamase enzymes [15,16]. \(\beta\)-lactamases that possess versatile hydrolytic capacities and therefore are able to hydrolyze carbapenems are called carbapenemases [15,16]. Some \(\beta\)-lactamases have carbapenemase activity and some do not. There are four major classes of \(\beta\)-lactamase based on molecular structure (class A, B, C and D) [16]. Class D \(\beta\)-lactamases, also known as oxacillinase (OXA), are the most common resistance factor against carbapenem in CNSAB isolates and have multiple subtypes [15,16]. OXA-51-like enzyme, that hydrolyzes carbapenems and penicillins, for example, is intrinsically possessed by *A. baumannii*. In addition, *A. baumannii* have acquired some carbapenemases including OXAs from the environment, and OXA-23-, OXA-40/24, and OXA-58-like enzymes are the most common detected in CNSAB. OXA-23-like enzyme is the most common driver of nosocomial outbreaks of CNSAB [15,16]. The less common causes of carbapenem resistance in CNSAB are class
B β-lactamases such as imipenemase (IMP), Verona integron-encoded metallo-β-lactamase (VIM), Seoul imipenemase (SIM) and New Delhi metallo-β-lactamase (NDM) [1,15,16]. Beta-lactamases are encoded by β-lactamase genes (bla). Several studies have been conducted to assess the genetic profiles of CNSAB isolates around the globe. A study in France found that bla_{OXA-23} was the most dominant gene in isolated CNSAB (82%) [17]. In Saudi Arabia, a study found that bla_{OXA-51} was detected in all isolated CNSAB as an intrinsic gene and bla_{OXA-23} was found to be the most predominant gene [18]. The same findings were reported from China [19,20]. Meanwhile, a study found that the bla_{OXA-23} is not yet widespread among A. baumannii in Japan [21].

Indonesia has the fourth highest population globally, with thousands of islands across its archipelago. National surveillance on antimicrobial resistance is challenging to conduct in the country [22]. In addition, only limited data are available on the molecular epidemiology of CNSAB in Indonesia, and therefore the origin and spread of antimicrobial resistance patterns cannot be fully understood [11]. In this study, we determined the genetic profiles of CNSAB isolates associated with bacteremia patients in 12 hospitals across the Indonesian archipelago using multiplex polymerase chain reaction (PCR) assay.

2. Results
2.1. Distribution of CNSAB Isolates and Patients’ Characteristics

A total of 123 CNSAB isolates were tested, of which 110 isolates carried the A. baumannii-specific gyrB gene, confirming the presence of A. baumannii species. The distribution of the CNSAB isolates based on the geographic locations and the number of beds of each hospital are provided in Figure 1.

Figure 1. Distribution of CNSAB isolates with confirmed gyrB gene from each hospital in Indonesia (n = 110). The percentage is calculated as the number of gyrB-positive isolates from each hospital divided by the total number of isolates carrying the gyrB in this study. The number of beds from each hospital are provided to increase understanding of the profile of the study site.

The characteristics of the patients with confirmed CNSAB based on gender and age are provided in Table 1. More than half of the patients were male (60%, 66/110) and 62.7% of the patients were aged between 15–64 years old, with a mean age of 39.3 (±24.2) years. Most of the patients (76.3%) were treated at an intensive care unit (Table 1).
Table 1. Characteristics of the bacteremia patients with confirmed CNSAB (n = 110).

| Characteristics | Group           | Frequency (%) |
|-----------------|-----------------|---------------|
| Sex             | Male            | 66 (60.0)     |
|                 | Female          | 44 (40.0)     |
| Age (years)     | <1              | 17 (15.5)     |
|                 | 1–14            | 10 (9.1)      |
|                 | 15–64           | 69 (62.7)     |
|                 | 65–70           | 10 (9.1)      |
|                 | >70             | 4 (3.6)       |
| Unit            | Intensive care unit | 84 (76.3) |
|                 | Non-intensive care unit | 26 (24.7) |

2.2. Antibiotic Resistance Test Results

Our data suggested that tigecycline was the most susceptible to CNSAB isolates followed by trimethoprim-sulfamethoxazole (TMP-SMX), amikacin, and fosfomycin. Out of 110 CNSAB isolates, less than half were sensitive to tigecycline (45.5%, 50/110) and TMP-SMX (38.2%, 42/110) (Figure 2). Most of the CNSAB isolates were resistant to cephalosporins, fluoroquinolone, aminoglycosides, and beta-lactam/beta-lactamase inhibitor antibiotics.

2.3. Distribution of the Carbapenemase Genes

This study detected seven carbapenemase genes which are commonly found in A. baumannii: \(\text{bla}_{\text{OXA-51-like}}, \text{bla}_{\text{OXA-23-like}}, \text{bla}_{\text{OXA-24-like}}, \text{bla}_{\text{OXA-48-like}}, \text{bla}_{\text{NDM-1}}, \text{bla}_{\text{VIM}}, \text{and bla}_{\text{IMP-1}}\), genes that encode for OXA-51-like, OXA-23-like, OXA-40/24-like, OXA-58-like, NDM-1, VIM, IMP-1 and IMP-1 enzyme. The \(\text{bla}_{\text{OXA-51-like}}\) gene, which is assumed to be an intrinsic gene of A. baumannii species, was detected in all CNSAB isolates (Table 2). The \(\text{bla}_{\text{OXA-23-like}}\) gene was the most prevalent carbapenemase gene detected (83.6%, 92/110), followed by \(\text{bla}_{\text{OXA-24-like}}\) gene (37.3%, 41/110). None of the isolates had the \(\text{bla}_{\text{OXA-48-like}}\) gene (Table 2).
Table 2. Distribution of the carbapenemase genes in CNSAB isolates from bacteremia patients in Indonesia (n = 110).

| Gene Distribution | Frequency (%) |
|-------------------|---------------|
| \(\text{bla}_{\text{OXA-51-like}}\) | 110 (100.0) |
| \(\text{bla}_{\text{OXA-23-like}}\) | 92 (83.6) |
| \(\text{bla}_{\text{OXA-24-like}}\) | 41 (37.3) |
| \(\text{bla}_{\text{OXA-48-like}}\) | 0 (0.0) |
| \(\text{bla}_{\text{NDM-1}}\) | 5 (4.5) |
| \(\text{bla}_{\text{VIM}}\) | 1 (0.9) |
| \(\text{bla}_{\text{IMP-1}}\) | 1 (0.9) |

**Gene combinations**

| Type | Frequency (%) |
|------|---------------|
| One gene | 83 (75.5) |
| \(\text{bla}_{\text{OXA-23-like}}\) | 66 (60.9) |
| \(\text{bla}_{\text{OXA-24-like}}\) | 17 (15.5) |
| Two-gene combinations | 25 (22.7) |
| \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{OXA-24-like}}\) | 21 (19.1) |
| \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{NDM-1}}\) | 2 (1.8) |
| \(\text{bla}_{\text{OXA-24-like}}/\text{bla}_{\text{NDM-1}}\) | 1 (0.9) |
| \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{IMP-1}}\) | 1 (0.9) |
| Three-gene combinations | 2 (1.8) |
| \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{OXA-24-like}}/\text{bla}_{\text{NDM-1}}\) | 1 (0.9) |
| \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{OXA-24-like}}/\text{bla}_{\text{VIM}}\) | 1 (0.9) |

IMP: imipenemase, NDM: New Delhi metallo-beta-lactamase, OXA: oxacillinase, VIM: Verona integron-encoded metallo-beta-lactamase.

By excluding \(\text{bla}_{\text{OXA-51-like}}\), our data revealed that 24.5% of CNSAB isolates carried more than one carbapenemase gene (Table 2). There were 22.7% (25/110) that had two carbapenemase genes with four combinations: \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{OXA-24-like}}\) 21 isolates; \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{NDM-1}}\) two isolates; \(\text{bla}_{\text{OXA-24-like}}/\text{bla}_{\text{NDM-1}}\) one isolate; and \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{IMP-1}}\) one isolate. Two (1.8%) isolates had three carbapenemase genes: \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{OXA-24-like}}/\text{bla}_{\text{NDM-1}}\) and \(\text{bla}_{\text{OXA-23-like}}/\text{bla}_{\text{OXA-24-like}}/\text{bla}_{\text{VIM}}\) for each isolate (Table 2).

The \(\text{bla}_{\text{OXA-23-like}}\) gene was the most prevalent carbapenemase gene in all research centers except in Persahabatan Hospital in Jakarta and Kandou Hospital in North Sulawesi. In Persahabatan Hospital, \(\text{bla}_{\text{OXA-24-like}}\) gene was the most prevalent (66.7%, 10/15), while at Kandou Hospital, \(\text{bla}_{\text{OXA-24-like}}\) and \(\text{bla}_{\text{NDM-1}}\) were the most dominant genes (Figure 3).

**Figure 3.** Carbapenemase genes’ distributions identified from 110 CNSAB isolates in 12 hospitals in Indonesia (n = 140). There are 140 genes identified from 110 isolated CNSAB. IMP: imipenemase, NDM: New Delhi metallo-beta-lactamase, OXA: oxacillinase, VIM: Verona integron-encoded metallo-beta-lactamase.
When we divided the study sites into two categories: Java (populated and developed island) and outside Java (less-populated and less-developed islands), the *bla*OXA-24-like gene was more dominant in Java compared to outside Java (41.8% vs. 15.8%), while *bla*NDM-1 and *bla*IMP-1-like were predominant outside Java (15.8% vs. 2.2% and 5.3% vs. 0.0%, respectively) (Table 3).

Table 3. Distribution of carbapenemase genes in CNSAB isolates based on geographics (Java vs. outside Java).

| Carbapenemase Gene | Java (n = 116) | Outside Java (n = 24) |
|--------------------|---------------|----------------------|
|                    | Frequency (%) | Frequency (%)        |
| *bla*OXA-23-like   | 75 (82.4)     | 17 (89.5)            |
| *bla*OXA-24-like   | 38 (41.8)     | 3 (15.8)             |
| *bla*NDM-1         | 2 (2.2)       | 3 (15.8)             |
| *bla*VIM           | 1 (1.1)       | 0 (0.0)              |
| *bla*IMP-1         | 0 (0.0)       | 1 (5.3)              |

IMP: imipenemase, NDM: New Delhi metallo-beta-lactamase, OXA: oxacillinase, VIM: Verona integron-encoded metallo-beta-lactamase.

2.4. Association between the Presence of Carbapenemase Genes and Antibiotic Resistance Tests

Since the most frequent carbapenemase genes identified among the isolated were *bla*OXA-23-like and *bla*OXA-24-like genes, the associations between the presence of these genes with the pattern of antibiotic resistance results were assessed. Our data suggested that the presence of *bla*OXA-23-like or *bla*OXA-24-like had a significant association with susceptibility to some antibiotics (Table 4). The percentage of susceptibility to cefoperazone-sulbactam was significantly lower in *bla*OXA-23-like-positive isolates than *bla*OXA-23-like negative isolates (1.1% vs. 33.3%, *p* < 0.001) However, in *bla*OXA-23-like-positive isolates, the percentage of susceptibility to TMP-SMX was significantly higher than CNSAB isolates without *bla*OXA-23-like (44.6% vs. 5.6%; *p* < 0.001) (Table 4).

Table 4. Association between the presence of *bla*OXA-23-like and *bla*OXA-24-like genes with antibiotic sensitivity tests.

| Name of Antibiotic          | *bla*OXA-23-like | *bla*OXA-24-like |
|-----------------------------|-----------------|-----------------|
|                             | Detected        | Not Detected    | *p*-Value | Detected    | Not Detected | *p*-Value |
| Ampicillin-sulbactam        | 2 (2.2)         | 0 (0.0)         | 1.000     | 0 (0.0)    | 2 (2.9)      | 0.528     |
| Non-susceptible             | 90 (97.8)       | 18 (100)        |           | 41 (100)   | 67 (97.1)    |           |
| Pipericillin-tazobactam     | 0 (0.0)         | 0 (0.0)         | NA        | 0 (0.0)    | 0 (0.0)      | NA        |
| Non-susceptible             | 92 (100)        | 18 (100)        | NA        | 41 (100)   | 68 (100)     | NA        |
| Cefazolin                   | 0 (0.0)         | 0 (0.0)         | NA        | 0 (0.0)    | 0 (0.0)      | NA        |
| Non-susceptible             | 92 (100)        | 18 (100)        | NA        | 41 (100)   | 69 (100)     | NA        |
| Ceftriaxone                 | 0 (0.0)         | 0 (0.0)         | NA        | 0 (0.0)    | 0 (0.0)      | NA        |
| Non-susceptible             | 92 (100)        | 18 (100)        | NA        | 41 (100)   | 69 (100)     | NA        |
| Cefazidime                  | 0 (0.0)         | 0 (0.0)         | NA        | 0 (0.0)    | 0 (0.0)      | NA        |
| Non-susceptible             | 92 (100)        | 18 (100)        | NA        | 41 (100)   | 69 (100)     | NA        |
| Cefepime                    | 0 (0.0)         | 0 (0.0)         | NA        | 0 (0.0)    | 0 (0.0)      | NA        |
| Non-susceptible             | 92 (100)        | 18 (100)        | NA        | 41 (100)   | 69 (100)     | NA        |
| Gentamicin                  | 3 (3.3)         | 1 (5.6)         | 0.516     | 1 (2.4)    | 3 (4.3)      | 1.000     |
| Non-susceptible             | 89 (96.7)       | 17 (94.4)       |           | 40 (97.6)  | 66 (95.7)    |           |
| Susceptible                 | 22 (23.9)       | 2 (11.1)        | 0.352     | 3 (7.3)    | 21 (30.4)    | 0.005*    |
| Amikacin                    | 70 (76.1)       | 16 (88.9)       |           | 38 (92.7)  | 48 (69.6)    | 0.295     |
| Non-susceptible             | 88 (95.7)       | 18 (100)        | 1.000     | 41 (100)   | 65 (94.2)    | 0.292     |
| Ciprofloxacin               | 4 (4.3)         | 0 (0.0)         |           | 0 (0.0)    | 3 (4.3)      |           |
| Non-susceptible             | 89 (95.7)       | 18 (100)        |           | 41 (100)   | 66 (95.7)    |           |
| Levofoxacin                 | 3 (3.3)         | 0 (0.0)         |           | 0 (0.0)    | 3 (4.3)      |           |
### Table 4. Cont.

| Name of Antibiotic | Antibiotic Susceptibility Result | bla\textsubscript{OXA-23-like} | p-Value | bla\textsubscript{OXA-24-like} | p-Value |
|-------------------|---------------------------------|-----------------|---------|-----------------|---------|
|                   | Detected                        | Not Detected    |         | Detected        | Not Detected |       |
| Tigecycline       | Susceptible                     | 41 (44.6)       | 9 (50.0) | 0.672           | 11 (26.8)    | 39 (56.5) | 0.002 * |
|                   | Non-susceptible                 | 51 (55.4)       | 9 (50.0) |                 | 30 (73.2)    | 30 (43.5) |            |
| Trimethoprim-     | Susceptible                     | 41 (44.6)       | 1 (5.6)  | 0.002 *         | 7 (17.1)     | 35 (50.7) | <0.001 ** |
| sulfamethoxazole  | Non-susceptible                 | 51 (55.4)       | 17 (44.4)|                 | 34 (82.9)    | 34 (49.3) |            |
| Fosfomycin        | Susceptible                     | 11 (12.0)       | 2 (11.1) | 1.000           | 6 (14.6)     | 7 (10.1)  | 0.547     |
|                   | Non-susceptible                 | 81 (88.0)       | 16 (88.9)|                 | 35 (85.4)    | 62 (89.9) |            |
| Cefoperazone-sulbactam | Susceptible       | 1 (1.1)         | 6 (33.3) | <0.001 **       | 6 (14.6)     | 1 (1.4)   | 0.010 *   |
|                   | Non-susceptible                 | 91 (98.9)       | 12 (66.7)|                 | 35 (85.4)    | 68 (98.6) |            |

* Significant at $p < 0.05$; ** Significant at $p < 0.001$; NA: not applicable, OXA: oxacillinase.

In CNSAB isolates that harbored \textit{bla\textsubscript{OXA-24-like}}, the percentage of susceptibility to amikacin, tigecycline and TMP-SMX was significantly lower than the CNSAB isolates without \textit{bla\textsubscript{OXA-24-like}}, by 7.3%** vs. 30.4%, 26.8% vs. 56.5%, and 17.1% vs. 50.7%, respectively. In contrast, the percentage of susceptible to cefoperazone-sulbactam was higher in \textit{bla\textsubscript{OXA-24-like}}-positive isolates compared to \textit{bla\textsubscript{OXA-24-like}}-negative isolates, at 14.6% vs. 1.4%; $p = 0.010$ (Table 4). Some antibiotic resistances were not associated with the presence of \textit{bla\textsubscript{OXA-23-like}} and \textit{bla\textsubscript{OXA-24-like}} genes (Table 4).

### 3. Discussion

This is the first multicenter study assessing the molecular epidemiology of CNSAB in Indonesia. Our study found that 76.3% of the CNSAB were isolated from bacteremia patients treated in the intensive care unit (ICU). The risk of bacteremia due to CNSAB increases because patients in the ICU generally have low immunity, use invasive devices, have surgery or other underlying diseases, or receive broad-spectrum antibiotics [23]. In the present study, some patients were neonates treated in the neonatal intensive care unit (NICU). Studies have reported that bacteremia-associated CNSAB were predominantly from those treated in the ICU and NICU [24–28].

Our study found that the CNSAB isolates were resistant to almost all classes of antibiotics such as cephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors and aminoglycosides. Our data found that tigecycline had the best sensitivity (45.45%). This antibiotic is used extensively in treating CNSAB-associated infections, usually in combination with other antibiotics. However, the efficacy of this antibiotic is still debated because it is bacteriostatic and has poor pharmacokinetics in the bloodstream and lungs [29,30], and therefore, in general, tigecycline is not recommended for bacteremia [30]. The sensitivity of tigecycline in our study was lower than in another study [31], possibly because tigecycline has been widely used in Indonesia.

The second highest sensitivity for CNSABs was TMP-SMX (38.18%). This sensitivity rate is relatively high in comparison with a previous review reporting that 22 out of 26 studies found that the CNSAB resistance rate to TMP-SMX was more than 80% [32]. This difference may be because TMP-SMX is only available in oral form in Indonesia, and the use of this antibiotic is therefore limited in outpatient settings to treat gastroenteritis or non-complicated urinary tract infections. Although antibiotic prescription and use in the outpatient setting is problematic, there is a need to measure and improve how clinicians prescribe and patients use antibiotics [33]. This data suggests that TMP-SMX is still a promising therapeutic option for CNSABs in Indonesia. A study found that TMP-SMX treatment in patients with severe infection was associated with a better clinical improvement and shorter hospital stay compared to colistin or ampicillin-sulbactam [34].

Other antibiotic options for CNSABs such as colistin and minocycline are not commercially available in Indonesia. The sensitivity tests for these two antibiotics are not routinely conducted in the country and therefore no sensitivity data are available for these two antibiotics. The high level of CNSAB resistance to all tested antibiotics in this study
urges that colistin and minocycline, or a new class of antibiotic, are urgently needed to treat CNSAB infection in Indonesia.

In our study, besides the intrinsic bla\textit{OXA-51-like} gene, the most prevalent carbapenemase gene identified in CNSAB isolates was bla\textit{OXA-23-like}. This is consistent with previous small studies from Indonesia \cite{24,35} and other countries around the world \cite{31,36–39}. Overall, 24.6% of CNSAB isolates had more than one carbapenemase gene, and this could contribute to an increase in minimum inhibitory concentration (MIC) due to higher hydrolytic activity, which may eventually lead to high resistance to beta lactam antibiotics \cite{38}. The bla\textit{OXA-24-like} gene was the second most prevalent in our study, and this gene was predominant in two hospitals: Persahabatan Hospital and Kandou Hospital, located in Jakarta and North Sulawesi, respectively. This is not surprising, since studies in other countries such as Spain and Portugal also have found that bla\textit{OXA-24-like} could be the predominant gene \cite{40,41}.

Based on geographical location, our study suggested that the distribution of bla\textit{OXA-24-like} and bla\textit{NDM-1} genes are different between Java and outside Java. Java, where the capital city Jakarta is located, has the largest population density and population mobility in Indonesia. The health services and facilities in Java are also more comprehensive than outside Java. Further investigation is warranted to determine the disproportional distribution of the carbapenemase genes between these two regions.

Several studies have been conducted to investigate the relationship between genotype profiles and drug resistance of multidrug-resistant \textit{A. baumannii}. A study conducted in Vietnam found that, with the exception of TMP-SMX, resistance to most antimicrobial agents was significantly related to the presence of \textit{bla\textit{OXA-23}} gene \cite{42}. A study in Saudi Arabia found there was an association between resistance to gentamicin and amikacin with the acquisition of insertion sequence \textit{ISAba1} upstream of \textit{bla\textit{OXA-51-like}} gene \cite{31}. Insertion sequence \textit{ISAba1} is associated with overexpression of the carbapenem genes \cite{42}. Another study found that \textit{A. baumannii} strains with two or more carbapenem genes had a high chance of being multidrug resistant \cite{42}. Our study found that the presence of the carbapenem genes were associated with resistance to some antibiotics (Table 4). For example, the presence of \textit{bla\textit{OXA-24-like}} was associated with resistance to amikacin, tigecycline and TMP-SMX, while \textit{bla\textit{OXA-23-like}} was associated with resistance to cefoperazone-sulbactam. OXA-24-like enzyme has the ability to hydrolyze penicillin and has weaker activity against cephalosporins and carbapenems \cite{1}. A study found that the \textit{bla\textit{OXA-24-like}} gene was almost completely resistant to amikacin, cefepime, ceftazidime, piperacillin/tazobactam and ampicillin/sulbactam \cite{43}. Meanwhile, OXA-23-like enzyme has the ability to hydrolyze carbapenems more significantly than other class D carbapenemase enzymes. This enzyme also can hydrolyze oxyimino cephalosporins, aztreonam, oxacillin, piperacillin and aminopenicillins \cite{1}. The mechanism through which OXA-23- and OXA-24-like enzyme impact tigecycline and TMP-SMX resistance is currently unclear.

This study has some limitations that need to be explained. Each study site had an uneven number of CNSAB isolates, which might distort the percentage of genes in each hospital. This is probably because the hospitals are different sizes. Second, due to unavailability of the antibiotics in the country, the current study is unable to provide sensitivity tests for colistin and minocycline against CNSAB.

4. Materials and Methods

4.1. Study Setting

A multicenter cross-sectional study was conducted in 12 hospitals in nine provinces across the Indonesian archipelago between September 2019 and March 2021. Out of the total hospitals, 10 of them serve as provincial referral hospitals. The study covered four Indonesian main islands: seven hospitals from Java, three hospitals from Sumatra, and one hospital each from Borneo (Kalimantan) and Sulawesi.
4.2. Bacterial Isolates

All CNSAB isolates were isolated from blood cultures of bacteremia patients. If more than one isolate was isolated from a patient, only the first isolate was analyzed in this study. Blood cultures were performed using the BacT/Alert (bioMérieux, Marcy l’Etoile, France) or BACTEC automated system (Becton Dickinson, Franklin Lakes, NJ, USA). The positive results were sub-cultured onto blood and MacConkey agar for further identification and antibiotic resistance tests, as recommended previously [24]. Identification and antibiotic resistance tests were carried out using an automated Vitek 2 System (bioMérieux, Marcy l’Etoile, France) or BD Phoenix (BD, Franklin Lakes, NJ, USA), followed the manufacturers’ protocols. The tested antibiotics were ampicillin-sulbactam, piperacillin-tazobactam, cefazoline, ceftriaxone, ceftazidime, cefepime, ceferoperoxaz-sulbactam, levofloxacin, ciprofloxacin, fosfomycin, gentamicin, amikacin, tigecycline, and TMP-SMX. The interpretation for tigecycline was referred to the FDA, while interpretation for ceferoperoxaz-sulbactam was based on the package insert breakpoints [44]. The antibiotics that were not included in those automated platforms were tested using the Kirby Bauer disc diffusion method [45], in which ceferoperoxaz-sulbactam and fosfomycin discs were 105 µg and 200 µg, respectively. The interpretation followed the Clinical and Laboratory Standards Institute (CLSI) [46]. CNSAB was defined if the culture had intermediate or resistance to one of the carbapenems (meropenem, imipenem or doripenem). All laboratories participating in this study included the quality control strains: Escherichia coli ATCC 25,922 and Pseudomonas aeruginosa ATCC 27853.

4.3. Confirmatory Test for A. baumannii

The molecular test to confirm the presence A. baumannii species was conducted at the Institute of Tropical Disease (ITD) at Universitas Airlangga in Surabaya. DNA extraction was carried out using the boiling method [47]. A multiplex PCR assay targeting A. baumannii-specific gyrB gene was used to confirm the A. baumannii species genotypically, as previously described [48,49]. The method is robust, reproducible, and cheaper than sequencing, and it enables us to identify most clinically relevant Acinetobacter species [48,49]. Two pairs of primers, designed to identify the gyrB gene of A. baumannii species [48,49], were used (Table 5).

Table 5. Primers used to identify the Acinetobacter baumannii species and carbapenemase genes.

| Target Gene | Primer Sequence (5’–3’ Amplicon (Base Pair) Reference |
|-------------|--------------------------------------------------------|
| gyrB | Sp2F: GTTCCTGTGATCCGAAATTCTCG 490 [48,49] Sp4R: AACGGAGCTTGTCAAGGTTA Sp4F: CACGCCGTAAGAGTGCATTA 294 [48,49] Sp4R: AACGGAGCTTGTCAAGGTTA |
| blaOXA-51-like | F: ATGAAACATTAAAACGACTCTTTAC 825 [36] R: CTATAAATACTAAATTTTGTTCT |
| blaIMP-1 | F: CTACCAGCAGCAGGTCTTTG 587 [50] R: AAACCAGTTTCCATTACCAT |
| blavIM | F: TGGGGCAATTGCAGCAGACAT 510 [50,51] R: ATGATTTTTTGTCAGCATC |
| blaNDM-1 | F: CTGGACCAACGCACTTGACC 754 [52] R: GCCCGTGATGAGTGATTGC |
| blaOXA-23-like | F: GATCGGATTGGAGAACCA GA 501 [53] R: ATCTTGACCGACATTTTGCAT |
| blaOXA-24-like | F: GATCGGATTGGAGAACCA GA 246 [53] R: ATCTTGACCGACATTTTGCAT |
| blaOXA-48-like | F: GATCGGATTGGAGAACCA GA 744 [54] R: ATCTTGACCGACATTTTGCAT |

F: forward primer; R: reverse primer.
The PCR amplification was carried out in 20 µL reaction solution consisting of 10 µL PCR mixture GoTaq Master Mix (Promega, Madison, WI, USA), 10 µM of each primer, 3 µL H₂O, and 5 µL of DNA template. Amplification was performed with an initial denaturation at 94 °C for 2 min, followed by 25 cycles consisting of denaturation at 94 °C for 1 min, annealing at 60 °C for 30 s, and extension at 72 °C for 1 min, with a final extension at 72 °C for 10 min [48].

4.4. Detection of Carbapenemase Genes

CNSAB isolates containing the gyrB gene were tested to detect the blaOXA-51-like gene and six other carbapenemase genes, which were divided into two multiplex PCR groups: one for detecting class B carbapenemases (blaIMP-1, blaVIM and blaNDM-1) and one for class D carbapenemases (blaOXA-23-like, blaOXA-24-like and blaOXA-48-like) [55]. The IMP and NDM have several sub-types. However, only IMP-1 and NDM-1 were assessed in this study because both are the main enzymes from IMP and NDM group in A. baumannii. The blaOXA-23-like, blaOXA-24-like and blaOXA-48-like genes were included since they are commonly reported from other countries including countries in Southeast Asia [15–20].

The primers to detect the carbapenemase genes are listed in Table 5. The amplification of all genes used a GoTaq PCR Master Mix (Promega, Madison, WI, USA). For blaOXA-51 gene detection, the total reaction volume was 25 µL, consisting of 12.5 PCR Master Mix, 10 pM forward and reverse primer, 5.5 H₂O and 5 µL DNA template. The amplification had 33 cycles with denaturation at 94 °C for 55 s, annealing at 46 °C for 45 s, and extension at 72 °C for 60 s [36]. For amplification of class B carbapenemase genes, the total reaction volume was 20 µL, consisting of 12.5 PCR Master Mix, 10 pM of each primer, 0.7 µL H₂O and 5 µL DNA template. The amplification conditions consisted of initial denaturation at 95 °C for 5 min, followed by 30 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s and extension at 72 °C for 30 s. The composition of the PCR mixture to detect class D carbapenemase genes was similar to class B. However, the amplification had slightly different conditions, with denaturation at 94 °C for 25 s, annealing at 52 °C for 40 s, and extension at 72 °C for 25 s. The amplicons of PCR amplifications were electrophoresed through ethidium bromide-stained 2% agarose gels at a voltage of 100 volts for 30 min. Visualization was conducted using a UV transilluminator and documented using a digital camera. Each PCR assay was accompanied with positive and negative controls. The positive control was obtained from the laboratory collection of the Institute of Tropical Disease at Universitas Airlangga.

4.5. Statistical Analysis

The association between the presence of carbapenemase genes and the antibiotic resistance profile was analyzed with chi-squared test. A p-value less than 0.05 was considered as significant. All analyses were conducted using a Statistical Package for the Social Sciences software version 28 (SPSS for Windows, Chicago, IL, USA).

5. Conclusions

The blaOXA-23-like gene is the most predominant gene in CNSAB isolates throughout Indonesia. The antibiotic resistance profiles of CNSAB in Indonesia are very worrying, and the distribution of the carbapenemase genes should receive more attention in the country. Continuous surveillance of antibiotic resistance in Indonesia needs to be strengthened to provide data on the antibiotic resistance burden in order to formulate a policy in the country and in the regions. Optimizing policy on the use of antibiotics and infection prevention and control in hospitals is very important and should be implemented throughout the country.

Author Contributions: Conceptualization, D.A., D.S., U.H. and K.K.; methodology, D.A., D.S., U.H. and K.K.; software, D.A.; validation, D.A., D.S., Y.R.S., P.D.E., C.C., L.S., Z.H., H.F., C.S., M.P., H.H., E.T., N.J., R.S., U.H. and K.K.; formal analysis, D.A., U.H. and K.K.; investigation, D.A., D.S., Y.R.S., P.D.E., C.C., L.S., Z.H., H.F., C.S., M.P., H.H., E.T., N.J., R.S., U.H. and K.K.; resources, D.A., W.S.,
U.H. and K.K.; data curation, D.A., U.H. and K.K.; writing—original draft preparation, D.A., U.H. and K.K.; writing—review and editing, D.A., D.S., Y.R.S., P.D.E., C.C., L.S., Z.H., H.F., C.S., M.P., H.H., E.T., N.J., R.S., U.H. and K.K.; visualization, D.A. and N.J.; supervision, U.H. and K.K.; project administration, D.A., N.J., R.S. and W.S.; funding acquisition, D.A., R.S., U.H. and K.K. All authors have read and agreed to the published version of the manuscript.

**Funding:** The study was funded by Indonesian Ministry of Higher Education (No. B/112/E3/RA.00/2021) and the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID). The APC was funded partly by Faculty of Medicine, Universitas Riau.

**Institutional Review Board Statement:** The protocol of the study was approved by the Ethical Review Committee of the Ethics Unit, Faculty of Medicine, Universitas Riau (B/133/UN19.5.1.1.8/UEPKK/2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The underlying data of this study are available from the corresponding author on request.

**Acknowledgments:** We would like to thank to the members of Indonesian Clinical Epidemiology Evidence Based Medicine (ICE_EBM) project and to Fajri Marindra for statistical consultation.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Nowak, P.; Paluchowska, P. *Acinetobacter baumannii*: Biology and drug resistance—Role of carbapenemases. Folia Histochem. Cytobiol. 2016, 54, 61–74. [CrossRef]
2. Durante-Mangoni, E.; Zarrilli, R. Global spread of drug-resistant *Acinetobacter baumannii*: Molecular epidemiology and management of antimicrobial resistance. Future Microbiol. 2011, 6, 407–422. [CrossRef]
3. Antunes, L.C.; Visca, P.; Towner, K.J. *Acinetobacter baumannii*: Evolution of a global pathogen. Pathog. Dis. 2014, 71, 292–301. [CrossRef]
4. Howard, A.; O'Donoghue, M.; Feeney, A.; Sleator, R.D. *Acinetobacter baumannii*: An emerging opportunistic pathogen. Virulence 2012, 3, 243–250. [CrossRef]
5. Montefour, K.; Frieden, J.; Hurst, S.; Helmich, C.; Headley, D.; Martin, M.; Boyle, D.A. *Acinetobacter baumannii*: An emerging multidrug-resistant pathogen in critical care. Crit. Care Nurse 2008, 28, 15–25; quiz 26. [CrossRef]
6. Sebény, P.J.; Riddle, M.S.; Petersen, K. *Acinetobacter baumannii* skin and soft-tissue infection associated with war trauma. Clin. Infect. Dis. 2008, 47, 444–449. [CrossRef]
7. Esterly, J.S.; Griffith, M.; Qi, C.; Malczynski, M.; Postelnick, M.J.; Scheetz, M.H. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of *Acinetobacter baumannii* bloodstream infections. Antimicrob. Agents Chemother. 2011, 55, 4844–4849. [CrossRef]
8. Doi, Y.; Murray, G.L.; Peleg, A.Y. *Acinetobacter baumannii*: Evolution of antimicrobial resistance-treatment options. Semin. Respir. Crit. Care Med. 2015, 36, 85–98. [CrossRef]
9. Lee, C.R.; Lee, J.H.; Park, M.; Park, K.S.; Bae, I.K.; Kim, Y.B.; Cha, C.J.; Jeong, B.C.; Lee, S.H. Biology of *Acinetobacter baumannii*: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options. Front. Cell. Infect. Microbiol. 2017, 7, 55. [CrossRef]
10. Rossi, I.; Royer, S.; Ferreira, M.L.; Campos, P.A.; Fuga, B.; Melo, G.N.; Machado, L.G.; Resende, D.S.; Batistao, D.; Urzedo, J.E.; et al. Incidence of infections caused by carbapenem-resistant *Acinetobacter baumannii*. Am. J. Infect. Control 2019, 47, 1431–1435. [CrossRef]
11. Hsu, L.Y.; Apsisarnthanarak, A.; Khan, E.; Suwantarat, N.; Ghafur, A.; Tambyah, P.A. Carbapenem-Resistant *Acinetobacter baumannii* and Enterobacteraeae in South and Southeast Asia. Clin. Microbiol. Rev. 2017, 30, 1–22. [CrossRef]
12. Karuniawati, A.; Saharman, Y.R.; Lestari, D.C. Detection of carbapenemase encoding genes in Enterobacteriaceae, Pseudomonas aeruginosa, and *Acinetobacter baumannii* isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011. Acta Med. Indones. 2013, 45, 101–106.
13. Kim, U.J.; Kim, H.K.; An, J.H.; Cho, S.K.; Park, K.H.; Jang, H.C. Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections. Chonnam. Med. J. 2014, 50, 37–44. [CrossRef]
14. Anggraini, D.; Santosaningsih, D.; Dwi Endraswari, P.; Moeihario, L.; Riezke, C.V.; Enty, E.; Marindra, F.; Verbrugh, H.A. Epidemiology study of *Acinetobacter* spp. isolated from blood culture in Indonesia. Int. J. Infect. Dis. 2020, 101, 62–63. [CrossRef]
15. Eichenberger, E.M.; Thaden, J.T. Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. Antibiotics 2019, 8, 37. [CrossRef]
16. Evans, B.A.; Amyes, S.G. OXA beta-lactamases. Clin. Microbiol. Rev. 2014, 27, 241–263. [CrossRef]

17. Jeannot, K.; Diancourt, L.; Vaux, S.; Thouverez, M.; Ribeiro, A.; Coignard, B.; Courvalin, P.; Brisse, S. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in France. PLoS ONE 2014, 9, e115452. [CrossRef]

18. Al-Agamy, M.H.; Shibli, A.M.; Ali, M.S.; Khubnani, H.; Radwan, H.H.; Livermore, D.M. Distribution of β-lactamases in carbapenem-nonsusceptible Acinetobacter baumannii in Riyadh, Saudi Arabia. J. Glob. Antimicrob. Resist. 2014, 2, 17–21. [CrossRef]

19. Zhang, Y.; Ding, F.; Luo, Y.; Fan, B.; Tao, Z.; Li, Y.; Gu, D. Distribution pattern of carbapenemases and solitary contribution to resistance in clinical strains of Acinetobacter baumannii. Ann. Palliat. Med. 2021, 10, 9184–9191. [CrossRef]

20. Zhang, Y.; Fan, B.; Luo, Y.; Tao, Z.; Nie, Y.; Wang, Y.; Ding, F.; Li, Y.; Gu, D. Comparative analysis of carbapenemases, RND family efflux pumps and biofilm formation potential among Acinetobacter baumannii strains with different carbapenem susceptibility. BMC Infect. Dis. 2021, 21, 841. [CrossRef]

21. Endo, S.; Yano, H.; Hirakata, Y.; Ariai, K.; Kanamori, H.; Ogawa, M.; Shimojima, M.; Ishibashi, N.; Aoyagi, T.; Hatta, M.; et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in Japan. Antimicrob. Chemother. 2012, 67, 1623–1626. [CrossRef]

22. Grundmann, H.; Klugman, K.P.; Walsh, T.; Ramon-Pardo, P.; Sigauque, B.; Khan, W.; Laxminarayan, R.; Heddini, A.; Stelling, J. A framework for global surveillance of antibiotic resistance. Drug Resist. Update 2011, 14, 79–87. [CrossRef]

23. Tacconelli, E.; Cataldo, M.A.; De Pascale, G.; Manno, D.; Spanu, T.; Cambieri, A.; Antonelli, M.; Sanguinetti, M.; Fadda, G.; Cauda, R. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J. Antimicrob. Chemother. 2008, 62, 1130–1137. [CrossRef]

24. Saharman, Y.R.; Karuniawati, A.; Sedono, R.; Aditianingsih, D.; Sudarmono, P.; Goessens, W.H.F.; Klaassen, C.H.W.; Verbrugh, H.A.; Severin, J.A. Endemic carbapenem-nonsusceptible Acinetobacter baumannii calcoaceticus complex in intensive care units of the national referral hospital in Jakarta, Indonesia. Antimicrob. Resist. Infec. Control 2018, 7, 5. [CrossRef]

25. Tjoa, E.; Moehario, L.H.; Rukmana, A.; Rohsiswatmo, R. Acinetobacter baumannii: Role in Blood Stream Infection in Neonatal Unit, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Int. J. Microbiol. 2013, 2013, 180763. [CrossRef]

26. Tsatsiou, O.; Josifidis, E.; Katragkou, A.; Dimou, V.; Sarafidis, K.; Karampatakis, T.; Antachopoulos, C.; Orfanou, A.; Tsakris, A.; Drossou-Agakidou, V.; et al. Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. Eur. J. Pediatr. 2015, 174, 65–74. [CrossRef]

27. Maciel, W.G.; da Silva, K.E.; Croda, J.; Cayo, R.; Ramos, A.C.; de Sales, R.O.; de Almeida de Souza, G.H.; Bampi, J.V.B.; Limiere, L.C.; Casagrande, J.C.; et al. Clonal spread of carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. J. Hosp. Infect. 2018, 98, 300–304. [CrossRef]

28. Ayobami, O.; Willrich, N.; Harder, T.; Okeke, I.N.; Eckmanns, T.; Markwart, R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: A systematic review and meta-analysis. Emerg. Microbes Infect. 2019, 8, 1747–1759. [CrossRef]

29. Piperaki, E.T.; Tzouvelekis, L.S.; Miriagou, V.; Daikos, G.L. Carbapenem-resistant Acinetobacter baumannii: In pursuit of an effective treatment. Clin. Microbiol. Infect. 2019, 25, 951–957. [CrossRef]

30. Doi, Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin. Infect. Dis. 2019, 69 (Suppl. S7), S565–S575. [CrossRef]

31. AlAmri, A.M.; AlQuayran, A.M.; Sebastian, T.; AlNimr, A.M. Molecular Surveillance of Multidrug-Resistant Acinetobacter baumannii. Curr. Microbiol. 2020, 77, 335–342. [CrossRef]

32. Falagas, M.E.; Vardakas, K.Z.; Roussos, N.S. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence. Int. J. Antimicrob. Agents 2015, 46, 231–241. [CrossRef]

33. Sanchez, G.V.; Fleming-Dutra, K.E.; Roberts, R.M.; Hicks, L.A. Core Elements of Outpatient Antibiotic Stewardship. MMWR Recomm. Rep. 2016, 65, 1–12. [CrossRef]

34. Raz-Pasteur, A.; Liron, Y.; Amir-Ronen, R.; Abdelgani, S.; Ohanyan, A.; Geffen, Y.; Paul, M. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study. J. Glob. Antimicrob. Resist. 2019, 17, 168–172. [CrossRef]

35. Nirwati, H.; Hakim, M.S.; Darma, S.; Mustafa, M.; Nuryastuti, T. Detection of blaOXA genes and identification of biofilm-producing capacity of Acinetobacter baumannii in a tertiary teaching hospital, Klaten, Indonesia. Med. J. Malaysia 2018, 73, 291–296.

36. Pournaras, S.; Gogou, V.; Giannouli, M.; Dimitrouli, E.; Dafopoulou, K.; Tsakris, A.; Zarrilli, R. Single-locus-sequence-based typing of blaOXA-51-like genes for rapid assignment of Acinetobacter baumannii clinical isolates to international clonal lineages. J. Clin. Microbiol. 2014, 52, 1653–1657. [CrossRef]

37. Kim, D.H.; Choi, J.Y.; Kim, H.W.; Kim, S.H.; Chung, D.R.; Peck, K.R.; Thamlikitkul, V.; So, T.M.; Yasin, R.M.; Hsueh, P.R.; et al. Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands. Antimicrob. Agents Chemother. 2013, 57, 5239–5246. [CrossRef]

38. Kazi, M.; Nikam, C.; Shetty, A.; Rodrigues, C. Dual-tubed multiplex-PCR for molecular characterization of carbapenemases isolated among Acinetobacter spp. and Pseudomonas spp. J. Appl. Microbiol. 2015, 118, 1096–1102. [CrossRef]

39. Goic-Barisic, I.; Kovacic, A.; Medic, D.; Jakovac, S.; Petrovic, T.; Tonkic, M.; Novak, A.; Rubic, Z.; Radic, M.; Milosavljevic, B.; et al. Endemicity of OXA-23 and OXA-72 in clinical isolates of Acinetobacter baumannii from three neighbouring countries in Southeast Europe. J. Appl. Genet. 2021, 62, 353–359. [CrossRef]
40. Ruiz, M.; Martí, S.; Fernandez-Cuenca, F.; Pascual, A.; Vila, J. High prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically related and unrelated *Acinetobacter baumannii* clinical isolates in Spain. *Clin. Microbiol. Infect.* 2007, 13, 1192–1198. [CrossRef]

41. Quinteira, S.; Grosso, F.; Ramos, H.; Peixe, L. Molecular epidemiology of imipenem-resistant *Acinetobacter* haemolyticus and *Acinetobacter baumannii* isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. *Antimicrob. Agents Chemother.* 2007, 51, 3465–3466. [CrossRef]

42. Hoang Quoc, C.; Nguyen Thi Phuong, T.; Nguyen Duc, H.; Tran Le, T.; Tran Thi Thu, H.; Nguyen Tuan, S.; Phan Trong, L. Carbapenemase Genes and Multidrug Resistance of *Acinetobacter baumannii*: A Cross Sectional Study of Patients with Pneumonia in Southern Vietnam. *Antibiotics* 2019, 8, 148. [CrossRef]

43. Quinteira, S.; Grosso, F.; Ramos, H.; Peixe, L. Molecular epidemiology of imipenem-resistant *Acinetobacter haemolyticus* and *Acinetobacter baumannii* isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital. *Antimicrob. Agents Chemother.* 2007, 51, 3465–3466. [CrossRef]

44. CEFOBID1. Cefoperazone Package Insert; Pfizer: New York, NY, USA, 2006.

45. Weinstein, M.P. *Performance Standards for Antimicrobial Susceptibility Testing*; Clinical and Laboratory Standards Institute: Pittsburgh, PA, USA, 2021.

46. Garcia, L.S. *Clinical Microbiology Procedures Handbook*; American Society for Microbiology Press: Washington DC, USA, 2010; Volume 1.

47. Dashti, A.A.; Jadaon, M.M.; Abdulsamad, A.M.; Dashti, M.H. Heat Treatment of Bacteri: A Simple Method of DNA Extraction for Molecular Techniques. *Kuwait Med. J.* 2009, 41, 117–122.

48. Higgins, P.G.; Wisplinghoff, H.; Krut, O.; Seifert, H. A PCR-based method to differentiate between *Acinetobacter baumannii* and *Acinetobacter* genomic species 13TU. *Clin. Microbiol. Infect.* 2007, 13, 1199–1201. [CrossRef]

49. Higgins, P.G.; Lehmann, M.; Wisplinghoff, H.; Seifert, H. gyrB multiplex PCR to differentiate between *Acinetobacter calcoaceticus* and *Acinetobacter* genomic species 3. *J. Clin. Microbiol.* 2010, 48, 4592–4594. [CrossRef]

50. Nishio, H.; Komatsu, M.; Shibata, N.; Shimakawa, K.; Sueyoshi, N.; Ura, T.; Satoh, K.; Toyokawa, M.; Nakamura, T.; Wada, Y.; et al. Metallo-β-Lactamase-Producing Gram-Negative Bacilli: Laboratory-Based Surveillance in Cooperation with 13 Clinical Laboratories in the Kinki Region of Japan. *J. Clin. Microbiol.* 2004, 42, 5256–5263. [CrossRef]

51. Nordmann, P.; Poirel, L. Emerging carbapenemases in Gram-negative aerobes. *Clin. Microbiol. Infect.* 2002, 8, 321–331. [CrossRef]

52. Pfeifer, Y.; Wilharm, G.; Zander, E.; Wichelhaus, T.A.; Gottig, K.P.; Seifert, H.; Witte, W.; Higgins, P.G. Molecular characterization of blaNDM-1 in an *Acinetobacter baumannii* strain isolated in Germany in 2007. *J. Antimicrob. Chemother.* 2011, 66, 1998–2001. [CrossRef]

53. Woodford, N.; Ellington, M.J.; Coelho, J.M.; Turton, J.F.; Ward, M.E.; Brown, S.; Amyes, S.G.; Livermore, D.M. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int. J. Antimicrob. Agents* 2006, 27, 351–353. [CrossRef]

54. Poirel, L.; Potron, A.; Nordmann, P. OXA-48-like carbapenemases: The phantom menace. *J. Antimicrob. Chemother.* 2012, 67, 1597–1606. [CrossRef] [PubMed]

55. Endraputra, P.N.; Kuntaman, K.; Wasito, E.B.; Shirakawa, T.; Raharjo, D.; Setyarini, W. Profile variation of bla genes among non-lactose fermenting Gram-negative bacilli between clinical and environmental isolates of Dr. Soetomo Hospital, Surabaya, Indonesia. *Biodiversitas* 2021, 22, 5047–5054. [CrossRef]